Crohn's disease trials recruiting in Minnesota

All Crohn's disease trials nationally

Cities in Minnesota

Recruiting trials in Minnesota

• 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
  NCT07273188 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Minnesota: Rochester
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Minnesota: Rochester
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Minnesota: Plymouth
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Minnesota: Minneapolis, Rochester
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Minnesota: Minneapolis, Rochester
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05995353 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Minnesota: Minneapolis
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Minnesota: Rochester
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  NCT06332534 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Minnesota: Minneapolis
• Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
  NCT06670638 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Minnesota: Rochester
• Helmsley 3.0: Abbreviated MRE
  NCT06533228 · Phase: Not specified · Ages: 10 Years and older · Sex: All (male and female) · Minnesota: Rochester
• Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
  NCT06864403 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Minnesota: Rochester
• Standardized Microbiota Transplant Therapy in Crohn's Disease
  NCT06631586 · Phase: Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · Minnesota: Minneapolis
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Minnesota: Rochester
• Treatment of Moderate to Severe Refractory Crohn's Disease
  NCT06721962 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Minnesota: Rochester